GenScript (1530.HK) Selected as a Finalist for the EY New Jersey Entrepreneur of the Year Award, with 2025 Revenue Expected to Surge 61%
Recognition of Global Bio CDMO Leadership and Innovative Management
Sherry Shao, CEO of GenScript Biotech Corporation (1530.HK), and Dr. Frank Zhang, co-founder, have been selected as finalists for the EY New Jersey Entrepreneur of the Year 2026 award. This nomination signifies more than just individual recognition; it validates GenScript's exceptional technological innovation and leadership in the global gene synthesis and biopharmaceutical CRO/CDMO markets. Through the advancement of its gene synthesis platform, GenScript has established itself as a key partner in the global R&D ecosystem, significantly enhancing its brand reputation within the industry. This differentiated reputation serves as a crucial intangible asset for attracting new clients and securing long-term projects in the highly competitive global outsourcing landscape.
Synergy from Subsidiary Legend Biotech's Successful CAR-T Drug
GenScript's innovative leadership is directly linked to the commercial success of Carvykti (ciltacabtagene autoleucel), an innovative BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapy developed by its subsidiary, Legend Biotech (LEGN). Carvykti has demonstrated remarkable efficacy in patients with multiple myeloma and received initial FDA approval in February 2022. In April 2024, its indication was expanded to include patients who have received prior treatment (second-line therapy). Legend Biotech has established a strong collaborative framework through a 50/50 global profit-sharing joint development and commercialization agreement with Janssen Biotech, a subsidiary of Johnson & Johnson, signed on December 17, 2017. The R&D achievements of its subsidiary serve as a catalyst for enhancing market perception of GenScript's platform technology and expanding opportunities for collaboration with global pharmaceutical companies.
Impressive Financial Performance Demonstrated by 61% Revenue Growth in 2025
In addition to its leadership reputation, GenScript is also attracting significant investor attention due to its impressive financial performance. GenScript's annual revenue for 2025 is projected to be approximately US$959.5 million, a remarkable 61.4% increase compared to US$594.5 million in 2024. This explosive growth is attributed to the increasing global demand for biotechnology research and the expansion of its high-value gene and cell therapy (GCT) CDMO business. Despite global inflation and macroeconomic uncertainties, GenScript's strong performance demonstrates the company's business sustainability and cash flow generation capabilities.
Strategies for Catching Up with Competitors and Securing Future Growth Drivers
In the global BCMA CAR-T market, Abecma (idecabtagene vicleucel) from Bristol Myers Squibb (BMS) is a major competing drug. GenScript is striving to enhance its market share by leveraging its technological advantages in gene synthesis to optimize the production process of Carvykti and stabilize its supply chain. Furthermore, the company plans to leverage its nomination for the EY Entrepreneur of the Year award to further promote joint R&D pipeline development with academic institutions and leading research laboratories, and to strengthen its recruitment efforts to attract top global research talent. In the long term, securing these human resources and expanding its technology collaboration network will serve as a solid foundation for solidifying its leadership in next-generation platforms.
GenScript (1530.HK) achieved a significant 61.4% year-over-year revenue growth in 2025, reaching approximately US$959.5 million, solidifying its dominant position in the global CRO and GCT CDMO markets. The commercial success of Carvykti, a BCMA CAR-T therapy co-developed with Janssen Biotech (a subsidiary of Johnson & Johnson) under a 50:50 profit-sharing agreement, which received FDA approval in 2022 and expanded its indication to second-line therapy in 2024, has been a key driver of this growth. This success provides a competitive advantage over competing drugs such as Abecma (BMS) and serves as a long-term reference point for demonstrating the reliability of the company's gene synthesis technology platform. The selection of its management team as finalists for the EY Entrepreneur of the Year award is expected to facilitate the attraction of global partnerships and the acquisition of key research personnel, thereby accelerating the development of next-generation pipelines. Therefore, from an investor perspective, this should be viewed not just as an award nomination, but as an opportunity to comprehensively assess GenScript's CDMO bidding competitiveness and the clinical value of its subsidiary's pipeline in the rapidly expanding market for multiple myeloma treatments.
Source: PR Newswire Biotech (rss_filter)